less invasive approach may be appealing. We will briefly review the available THV options ( Table 1) .
ANCHORING IN THE ASCENDING AORTA
The CoreValve (Medtronic, Minneapolis, Minnesota) has been used with some success in the absence of valvular calcification. The very long frame anchors not only in the aortic annulus, but also extends up to the supracoronary aorta, improving stability. Several registries document the feasibility in patients with pure AR (1-3). In high surgical risk patients with pure AR, the 30-day mortality rate has ranged from 9.3% to 23%, the stroke rate from 0% to 4.7%, and the need for new pacemakers from 7.5% to 27.3%.
Residual AR that is greater than mild remained in 20.9% to 23%. In the largest series to date (n ¼ 43), a second THV was needed in 18.6% of patients, and 
REPOSITIONABLE VALVES
The CoreValve's successor, the Evolut R (Medtronic), represents an attractive advance. This THV can be partially, but not fully, deployed and yet be recaptured in its delivery catheter and repositioned or removed if needed.
Taking repositionability a step further, the inflat- Medical. Dr. Htun has reported that he has no relationships relevant to the contents of this paper to disclose.
SELF-POSITIONING GEOMETRY
Some THVs incorporate self-seating geometry that facilitates optimal positioning within the annulus. 
ARCHES, FEELERS, AND GRASPERS
Other valves have taken self-positioning a step further, incorporating design elements that use the leaflets of the native valve to assist in THV positioning and fixation.
The Engager (Medtronic) incorporates 3 nitinol wire "arches" that, using a transapical approach, are exposed in the aorta and withdrawn until they contact the 3 native cusps; at this point, the selfexpanding THV is unsheathed and expanded. Experience with this device in pure AR is limited to isolated reports (7).
JenaValve (JenaValve Technology, Munich, Germany) incorporates 3 nitinol wire "feelers" that, using a transapical approach, are similarly exposed in the aorta and withdrawn until these contact the native cusps. As the self-expanding frame is unsheathed, the native leaflets The survival rate at 6 months was 80.7%. Schlingloff et al. 
THE IDEAL VALVE?
Surgery remains the gold standard for pure AR, although current THVs may offer an option for some 
